Inventor · disambiguated record
Paul S. Shapiro
Also filed as: SHAPIRO PAUL · SHAPIRO PAUL S
10 granted patents·12 pending applications·171 citations·filing 2005–2025
88Inventor score
Top patents by PatentIndex Score
22 records- 0196US11357781B2Non-catalytic substrate-selective, p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereofUNIV MARYLAND·Filed 2021·Granted Jun 14, 2022·10 cites·21 claims
- 0296US11078171B2Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitorsUNIV MARYLAND·Filed 2020·Granted Aug 3, 2021·13 cites·13 claims
- 0394US11718595B2Non-ATP/catalytic site p38 Mitogen Activated Protein Kinase inhibitorsUNIV MARYLAND·Filed 2021·Granted Aug 8, 2023·4 cites·19 claims
- 0493US11911393B2Non-catalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereofUNIV MARYLAND·Filed 2023·Granted Feb 27, 2024·1 cites·17 claims
- 0592US8834568B2Surgical technique using a contoured allograft cartilage as a spacer of the carpo-metacarpal joint of the thumb or tarso-metatarsal joint of the toeSHAPIRO PAUL S·Filed 2011·Granted Sep 16, 2014·133 cites·18 claims
- 0691US11911392B2Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereofUNIV MARYLAND·Filed 2022·Granted Feb 27, 2024·1 cites·20 claims
- 0790US9115122B2Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK)SHAPIRO PAUL S·Filed 2013·Granted Aug 25, 2015·9 cites·4 claims
- 0884US2025100985A1NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORSUNIV MARYLAND·Filed 2024·Application pending·0 cites
- 0982US12404259B2Inhibitors of extracellular signal-regulated kinaseGEN1E LIFESCIENCES INC·Filed 2024·Granted Sep 2, 2025·0 cites·12 claims
- 1082US2024366619A1NON-CATALYTIC SUBSTRATE-SELECTIVE p38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOFUNIV MARYLAND·Filed 2024·Application pending·0 cites
- 1181US12202810B2Non-ATP/catalytic site p38 mitogen activated protein kinase inhibitorsUNIV MARYLAND·Filed 2023·Granted Jan 21, 2025·0 cites·18 claims
- 1277US2025353826A1Inhibitors of extracellular signal-regulated kinaseGEN1E LIFESCIENCES INC·Filed 2025·Application pending·0 cites
- 1363US2007066616A1Inhibitors for extracellular signal-regulated kinase docking domains and uses thereforSHAPIRO PAUL·Filed 2006·Application pending·0 cites
- 1462US2019151324A1NON-CATALYTIC SUBSTRATE-SELECTIVE P38alpha-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOFUNIV MARYLAND·Filed 2017·Application pending·0 cites
- 1561US2009299063A1Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses ThereforSHAPIRO PAUL·Filed 2006·Application pending·0 cites
- 1653US2023140941A1Non-atp/catalytic site p38 mitogen activated protein kinase inhibitorsUNIV MARYLAND·Filed 2021·Application pending·0 cites
- 1752US9198763B2Surgical technique using a contoured allograft cartilage as a spacer of the carpo-metacarpal joint of the thumb or tarso-metatarsal joint of the toeSHAPIRO PAUL S·Filed 2014·Granted Dec 1, 2015·0 cites·20 claims
- 1847US2020308591A1Promoter region analysis methods and cells for practicing sameEUROFINS DISCOVERX CORP·Filed 2020·Application pending·0 cites
- 1942US2019076139A1Embroidered tissue buttonARTHREX INC·Filed 2017·Application pending·0 cites
- 2040US2005209299A1Inhibition of mixed lineage kinases and uses thereforUNIV MARYLAND·Filed 2005·Application pending·0 cites
- 2136US2016144137A1Retractable insulin infusion systemSHAPIRO PAUL S·Filed 2015·Application pending·0 cites
- 2234US2011116804A1Hands-free sterile field remote control apparatusSHAPIRO PAUL S·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul S. Shapiro files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →